Changing profile of rotavirus genotypes in Bangladesh, 2006–2012

BMC Infectious Diseases

Mustafizur Rahman¹  Tasnim Azim¹  Abu Syed Golam Faruque¹  Sumon Kumar Das¹  Subarna Barua¹  Sayra Moni¹  Saiada Farjana¹  Zahid Hassan¹  Mokibul Hassan Afrad¹ 

[1] Virology Laboratory, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka 1212, Bangladesh

关键词: Epitope;    Genotype;    Bangladesh;    Vaccine;    Diarrhea;    Rotavirus;   

Others  :  1147056
DOI  :  10.1186/1471-2334-13-320

 received in 2013-02-17, accepted in 2013-07-09,  发布年份 2013

【 摘 要 】

Background

Rotavirus is the leading cause of severe diarrhea in infants and young children worldwide including Bangladesh. Unlike what was seen in high-income countries, the licensed rotavirus vaccines did not show high efficacy in Bangladeshi trials. We assessed rotavirus prevalence and genotypes in Bangladesh over six-year period to provide baseline information on the rotavirus burden and changing profile in the country.

Methods

This study was conducted from June 2006 to May 2012 in Matlab, Bangladesh. Group A rotaviruses were detected in stools collected from diarrhea patients by ELISA and genotyped using multiplex reverse transcription PCR followed by nucleotide sequencing.

Results

Of the 9678 stool samples, 20.3% were positive for rotavirus. The most predominant genotype was G1P[8] (22.4%), followed by G9P[8] (20.8%), G2P[4] (16.9%) and G12P[8] (10.4%). Mixed infections were detected in 14.2% of the samples. Emergence of an unusual strain, G9P[4] was documented during 2011–12. Several amino acid mismatches in the antigenic epitopes of VP7 and VP4 between Bangladeshi and the vaccine strains were identified.

Conclusions

Our study provides important information on rotavirus genotypes that should be considered for the selection and introduction of rotavirus vaccines in Bangladesh.

【 授权许可】

   
2013 Afrad et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI: Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(Suppl 1):S9-S15.
• [2]Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD: Rotavirus vaccines: targeting the developing world. J Infect Dis 2005, 192(Suppl 1):S160-166.
• [3]Estes M: Rotaviruses and their replication, 4th ed. edn. Philadelphia: Lippincott Williams & Wilkins; 2001.
• [4]Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Banyai K, Brister JR, Buesa J, Esona MD, Estes MK, Gentsch JR, et al.: Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol 2011, 156(8):1397-1413.
• [5]Trojnar E, Sachsenroder J, Twardziok S, Reetz J, Otto PH, Johne R: Identification of an avian group A rotavirus containing a novel VP4 gene with a close relationship to those of mammalian rotaviruses. J Gen Virol 2013, 94(Pt 1):136-142.
• [6]Dunn SJ, Cross TL, Greenberg HB: Comparison of the rotavirus nonstructural protein NSP1 (NS53) from different species by sequence analysis and northern blot hybridization. Virology 1994, 203(1):178-183.
• [7]Dyall-Smith ML, Lazdins I, Tregear GW, Holmes IH: Location of the major antigenic sites involved in rotavirus serotype-specific neutralization. Proc Natl Acad Sci U S A 1986, 83(10):3465-3468.
• [8]Ward RL, Bernstein DI: Rotarix: a rotavirus vaccine for the world. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009, 48(2):222-228.
• [9]Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, Lopez P, Macias-Parra M, Ortega-Barria E, Rivera-Medina DM, et al.: Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(9619):1181-1189.
• [10]Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al.: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
• [11]Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A: Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(9601):1757-1763.
• [12]Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
• [13]Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, et al.: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.
• [14]Detailed Review Paper on Rotavirus Vaccines. WHO Strategic Advisory Group of Experts (SAGE) on Immunization 2009. Available from: http://www.who.int/immunization/sage/3_Detailed_Review_Paper_on_Rota_Vaccines_17_3_ 2009.pdf webcite
• [15]Taneja DK, Malik A: Burden of rotavirus in India - Is rotavirus vaccine an answer to it? Indian J Publ health 2012, 56:17-21.
• [16]Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, Datta SK, Suryakiran PV, Delem A, Han HH, et al.: Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human vaccines 2009, 5(6):414-419.
• [17]Hoshino Y, Jones RW, Ross J, Honma S, Santos N, Gentsch JR, Kapikian AZ: Rotavirus serotype G9 strains belonging to VP7 gene phylogenetic sequence lineage 1 may be more suitable for serotype G9 vaccine candidates than those belonging to lineage 2 or 3. J Virol 2004, 78(14):7795-7802.
• [18]Estes MK: Rotaviruses and their replication. In., 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2001.
• [19]Rahman M, Sultana R, Ahmed G, Nahar S, Hassan ZM, Saiada F, Podder G, Faruque AS, Siddique AK, Sack DA, et al.: Prevalence of G2P[4] and G12P[6] rotavirus, Bangladesh. Emerg Infect Dis 2007, 13(1):18-24.
• [20]Herring AJ, Inglis NF, Ojeh CK, Snodgrass DR, Menzies JD: Rapid diagnosis of rotavirus infection by direct detection of viral nucleic acid in silver-stained polyacrylamide gels. J Clin Microbiol 1982, 16(3):473-477.
• [21]Kobayashi N, Lintag IC, Urasawa T, Taniguchi K, Saniel MC, Urasawa S: Unusual human rotavirus strains having subgroup I specificity and "long" RNA electropherotype. Arch Virol 1989, 109(1–2):11-23.
• [22]Kawai K, O'Brien MA, Goveia MG, Mast TC, El Khoury AC: Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine 2012, 30(7):1244-1254.
• [23]Miles MG, Lewis KD, Kang G, Parashar UD, Steele AD: A systematic review of rotavirus strain diversity in India, Bangladesh, and Pakistan. Vaccine 2012, 30(Suppl 1):A131-139.
• [24]Unicomb LE, Podder G, Gentsch JR, Woods PA, Hasan KZ, Faruque AS, Albert MJ, Glass RI: Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995. J Clin Microbiol 1999, 37(6):1885-1891.
• [25]Iturriza-Gomara M, Isherwood B, Desselberger U, Gray J: Reassortment in vivo: driving force for diversity of human rotavirus strains isolated in the United Kingdom between 1995 and 1999. J Virol 2001, 75(8):3696-3705.
• [26]Zeller M, Rahman M, Heylen E, De Coster S, De Vos S, Arijs I, Novo L, Verstappen N, Van Ranst M, Matthijnssens J: Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28(47):7507-7513.
• [27]Hull JJ, Teel EN, Kerin TK, Freeman MM, Esona MD, Gentsch JR, Cortese MM, Parashar UD, Glass RI, Bowen MD: United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 2011, 30(1 Suppl):S42-47.
• [28]Jin Q, Ward RL, Knowlton DR, Gabbay YB, Linhares AC, Rappaport R, Woods PA, Glass RI, Gentsch JR: Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses. Arch Virol 1996, 141(11):2057-2076.
• [29]Parashar UD, Glass RI: Rotavirus vaccines–early success, remaining questions. N Engl J Med 2009, 360(11):1063-1065.
• [30]Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI: Oral rotavirus vaccines: how well will they work where they are needed most. J Infect Dis 2009, 200(Suppl 1):S39-48.